KINE-501D

KINE-501D is a peptide-based therapeutic candidate developed by Kine Science, specifically designed for the treatment of Parkinson's disease. It is part of the company's proprietary M3 (Microglia Modulating Molecules) platform, which focuses on the modulation of microglial cells to address neurodegenerative conditions. Microglia are the primary immune cells of the central nervous system, and their chronic activation is a key driver of neuroinflammation and dopaminergic neuron loss in Parkinson's disease. KINE-501D aims to regulate microglial activity, shifting these cells from a pro-inflammatory state to a neuroprotective one, thereby potentially slowing disease progression. As of the latest reports, the asset is in the discovery or early preclinical stage of development.